The Utilization of a New Strength Citrate Anticoagulant during Centrifugal Plateletpheresis: I. ASSESSMENT OF DONOR EFFECTS

Publisher Website
Google Scholar
Abstract
A reduction of donor effects during centrifugal plateletpheresis with the Hemonetics Blood Processor was achieved by reducing the concentration of the citrate anticoagulant. Serum citrate and ionized Ca levels, immediately and 1 h post-pheresis, were affected to a lesser extent by using 5.0 g total ionized citrate (TIC) than with either 8.0 g or 11.0 g. Tctal Ca, bicarbonate, prothrombin time, partial thromboplastin time, ECG and platelet counts were affected to a similar degree by all 3 TIC formulations. The total number of platelets collected per liter of blood processed was not significantly different among the 3 TIC formulations. In vitro studies employing the screen filtration pressure (SFP) technique showed no evidence of platelet aggregates in whole blood collected into either 0.01 M or 0.005 M citrate and agitated or left stationary at room temperature for 5 h. The use of different citrate concentrations in plateletpheresis is discussed.